Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma

British Journal of Cancer

Volumn 94, Issue 10, 2006, Pages 1402-1406

  Park, S R ^a   Chun, J H ^a   Yu, M S ^a   Lee, J H ^a   Ryu, K W ^a   Choi, I J ^a   Kim, C G ^a   Lee, J S ^a   Kim, Y W ^a   Bae, J M ^a   Kim, H K ^a,b  

^a National Cancer Center   (South Korea)

^b Hematologic Oncology Clinic   (South Korea)

Author keywords

Docetaxel; Gastric cancer; Irinotecan

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; PHENIRAMINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; OVARY METASTASIS; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 33646844276     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603133     Document Type: Article

References (21)

1. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C (2002) CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94: 641-646
2. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23: 5660-5667
3. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32: 248-254
4. Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, Goker E, Risse M, Awad L, Bugatet R (2005) Randomized phase 3 trial of irinotecan (CPT-11)+5-FU/folinic acid (FA) vs CDDP+5-FU in 1st-line advanced gastric cancer patients. Proc Am Soc Clin Oncol 23: 308s (abstract no. 4003)
5. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastro-intestinal Cancer Study Group. Gan To Kagaku Ryoho 21: 1033-1038
6. Hawkins R, Cunningham D, Soerbye H, Adenis A, Canon J-L, Lopez-Vivanco G, Jacques C, Stenger P, Zuber E, Misset J-L (2003) Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 22: 257 (abstract no. 1032)
7. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ, American Cancer Society (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8-29
8. Kettner E, Ridwelski K, Keilholz U, Gallkowski U, Gebauer T, Kröning H, Eichelmann K, Fahlke J, Lippert H (2001) Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: Results of two phase II studies. Proc Am Soc Clin Oncol 20: 165 (abstract no. 657)
9. Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ (2003) Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multi-centric trial. Br J Cancer 89: 997-1001
10. Lim WT, Lim ST, Wong NS, Koo WH (2003) CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians. J Chemother 15: 400-405
11. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ, Van Cutsem E (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 23: 308s (abstract no. 4002)
12. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21: 54-59
13. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R (2004) Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15: 1773-1781
14. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12: 47-51
15. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11: 301-306
16. Shin HR, Jung KW, Won YJ, Park JG (2004) 2002 Annual Report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 36: 103-114
17. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
18. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70: 380-383
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
20. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648-2657
21. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267